Clinical queries: 0800 466 863

Education office: 0800 882 873

Bexsero funded for special groups from 1 July 2021

PHARMAC has announced the addition of funded Bexsero for certain special groups who are close contacts of a meningococcal disease case or who have a higher risk of meningococcal disease from 1 July 2021.

In summary, Bexsero (meningococcal group B) vaccination will be funded for people who are:

  • close contacts of meningococcal cases of any meningococcal group (e.g. A, C, W, Y or B),
  • at higher risk of meningococcal B disease because they:
    • are pre- or post-splenectomy
    • have functional or anatomic asplenia
    • have HIV
    • have complement deficiency
    • are pre- or post-solid organ transplant
    • are post-bone marrow transplant
    • are pre- or post-immunosuppression that will be/is longer than 28 days.

The Pharmaceutical Schedule eligibility for Bexsero (meningococcal group B) vaccination:

Section I

Either:

A) Both:

  1. Child is under one year of age; and
  2. Any of the following:
    1. up to three doses for patients pre- and post-splenectomy and for patients with functional or anatomic asplenia, HIV, complement deficiency (acquired or inherited), or pre- or post-solid organ transplant; or
    2. up to three doses for close contacts of meningococcal cases of any group; or
    3. up to three doses for child who has previously had meningococcal disease of any group; or
    4. up to three doses for bone marrow transplant patients; or
    5. up to three doses for child pre- and post-immunosuppression*; or

B) Both:

  1. Person is one year of age and over; and
  2. Any of the following:
    1. up to two doses and a booster every five years for patients pre- and post-splenectomy and for patients with functional or anatomic asplenia, HIV, complement deficiency (acquired or inherited), or pre- or post-solid organ transplant; or
    2. up to two doses for close contacts of meningococcal cases of any group; or
    3. up to two doses for person who has previously had meningococcal disease of any group; or
    4. up to two doses for bone marrow transplant patients; or
    5. up to two doses for person pre- and post-immunosuppression*

*Immunosuppression due to corticosteroid or other immunosuppressive therapy must be for a period of greater than 28 days.

Section H

Restricted

Initiation – Infants under one year of age

Any of the following:

  1. up to three doses for patients pre- and post-splenectomy and for patients with functional or anatomic asplenia, HIV, complement deficiency (acquired or inherited), or pre- or post-solid organ transplant; or
  2. up to three doses for close contacts of meningococcal cases of any group; or
  3. up to three doses for child who has previously had meningococcal disease of any group; or
  4. up to three doses for bone marrow transplant patients; or
  5. up to three doses for person pre- and post-immunosuppression*

Initiation – Person is one year of age and over

Any of the following:

  1. up to two doses and a booster every five years for patients pre- and post-splenectomy and for patients with functional or anatomic asplenia, HIV, complement deficiency (acquired or inherited), or pre- or post-solid organ transplant; or
  2. up to two doses for close contacts of meningococcal cases of any group; or
  3. up to two doses for person who has previously had meningococcal disease of any group; or
  4. up to two doses for bone marrow transplant patients; or
  5. up to two doses for person pre- and post-immunosuppression*

*Immunosuppression due to corticosteroid or other immunosuppressive therapy must be for a period of greater than 28 days.

Last updated: Jun 2021